Chariton Pharmaceuticals

Chariton Pharmaceuticals was established in 2022 in Cambridge, MA as a subsidiary of SDG, LLC, after acquiring the platform and lead drug candidate technology and intellectual property from OsteoAnalgesia, Inc. We are a drug development company focused on bringing to market new therapies for rheumatoid arthritis and pain. Despite advancements in biologics and other therapies to treat rheumatoid arthritis, there remains a major unmet need in this debilitating disease. Our mission is to relieve the suffering associated with rheumatoid arthritis using our propriety polymer pro-drug technology to develop a reformulation of dexamethasone, CP-001, with optimized delivery of the active ingredient only to sites of inflammation rendering it free of the dose and duration of use limiting systemic side effects. Through a previous pharmaceutical company partnership, CP-001 has undergone considerable early development that has made it the first in class to achieve critical, and industry first, benchmarks of development.